Summa Equity, a thematic investment company with Nordic focus, agreed to invest in Sengenics, a functional proteomics company. Financial terms were not disclosed. "Sengenics’ proprietary technology unlocks tremendous potential for researchers around the world to further their understanding of biology and disease. We are proud to partner with the company and support its journey, as it looks to expand its position in the market and grow its business. We look forward to supporting the Sengenics team in our shared ambition to invest to drive product development, global expansion and accelerated adoption," Tommi Unkuri, Summa Equity Partner.